Research Papers: Immunology:

Minocycline promotes the generation of dendritic cells with regulatory properties

Narae Kim, Chan-Su Park, Sun-A Im, Ji-Wan Kim, Jae-Hee Lee, Young-Jun Park, Sukgil Song and Chong-Kil Lee _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:52818-52831. https://doi.org/10.18632/oncotarget.10810

Metrics: PDF 1353 views  |   HTML 2724 views  |   ?  


Narae Kim1,*, Chan-Su Park1,*, Sun-A Im1, Ji-Wan Kim1, Jae-Hee Lee1, Young-Jun Park1, Sukgil Song1 and Chong-Kil Lee1

1 College of Pharmacy, Chungbuk National University, Cheongju, South Korea

* These authors have contributed equally to this work

Correspondence to:

Chong-Kil Lee, email:

Keywords: minocycline, dendritic cell, growth promotion, regulatory property, CD4 Tregs, Immunology and Microbiology Section, Immune response, Immunity

Received: January 02, 2016 Accepted: July 13, 2016 Published: July 24, 2016


Minocycline, which has long been used as a broad-spectrum antibiotic, also exhibits non-antibiotic properties such as inhibition of inflammation and angiogenesis. In this study, we show that minocycline significantly enhances the generation of dendritic cells (DCs) from mouse bone marrow (BM) cells when used together with GM-CSF and IL-4. DCs generated from BM cells in the presence of minocycline (Mino-DCs) demonstrate the characteristics of regulatory DCs. Compared with control DCs, Mino-DCs are resistant to subsequent maturation stimuli, impaired in MHC class II-restricted exogenous Ag presentation, and show decreased cytokine secretion. Mino-DCs also show decreased ability to prime allogeneic-specific T cells, while increasing the expansion of CD4+CD25+Foxp3+ T regulatory cells both in vitro and in vivo. In addition, pretreatment with MOG35-55 peptide-pulsed Mino-DCs ameliorates clinical signs of experimental autoimmune encephalitis induced by MOG peptide injection. Our study identifies minocycline as a new pharmacological agent that could be potentially used to increase the production of regulatory DCs for cell therapy to treat autoimmune disorders, allergy, and transplant rejection.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10810